Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026

The U.S. Food and Drug Administration on Thursday granted 510(k) clearance for Becton, Dickinson and Company’s (NYSE:BDX) new breast biopsy system.The FDA approved BD’s EnCor EnCompass Breast Biopsy and Tissue Removal System, which is expected to hit the market in early 2026.This system is designed to enhance the biopsy experience by allowing clinicians to perform procedures across various breast imaging modalities.The EnCor EnCompass system features advanced capabilities, including high and low vacuum stre ...